Prevalence of Hypogonadism in Newly Detected Type 2 Diabetes Mellitus Male Patients (Code-T0138)

Introduction: Hypogonadism, a condition marked by low testosterone and related symptoms, is commonly associated with type 2 diabetes mellitus (T2DM). Early identification in newly diagnosed T2DM patients can provide critical insights into its prevalence and associated risk factors, potentially guiding better management strategies.

Aims and Objectives:

Aim:

To study prevalence of hypogonadism in newly detected T2DM male patients attending tertiary care hospital.

Primary objective:

To study prevalence of hypogonadism in newly detected T2DM male patients.

Secondary objective:

To study predictors of hypogonadism in newly detected T2DM male patients.

Methods: A cross-sectional observational study was conducted on 90 newly diagnosed male T2DM patients aged 25–60 years. Data on demographics, anthropometry, and clinical history were collected. Screening for hypogonadism was performed using the ADAM questionnaire and biochemical assays, defining low testosterone levels as <300 ng/dL. Statistical analyses included independent t-tests, chi-square tests, and logistic regression to identify significant risk factors.

Results: Hypogonadism was observed in 16.67% of participants, with 48.89% reporting symptoms via the ADAM questionnaire. Primary and secondary hypogonadism were differentiated based on FSH and LH levels. Obesity, increased HbA1c, and lipid abnormalities showed significant correlations with hypogonadism. Multivariate analysis identified obesity and elevated fasting insulin levels as independent predictors.

Conclusion: Hypogonadism is prevalent in a notable subset of newly diagnosed T2DM male patients. Incorporating routine screening for hypogonadal symptoms and hormonal evaluation at diagnosis can enable timely intervention, improving patient outcomes and reducing long-term complications.

Keywords: Hypogonadism, Type 2 Diabetes Mellitus, Testosterone Deficiency, ADAM Questionnaire, Obesity, Risk Factors